Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3receptors with preferential binding to the D3receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A. Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
Cariprazine add-on in inadequate clozapine response: A report on two cases / De Berardis, D.; Rapini, G.; Olivieri, L.; Giardini, A.; De Lauretis, I.; Serroni, N.; Orsolini, L.; Fornaro, M.; Iasevoli, F.; Trotta, S.; Cottura, P.; Vellante, F.; Alessandrini, M.; Di Giannantonio, M.. - In: CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE. - ISSN 1738-1088. - 19:1(2021), pp. 174-178. [10.9758/CPN.2021.19.1.174]
Cariprazine add-on in inadequate clozapine response: A report on two cases
Orsolini L.;
2021-01-01
Abstract
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2/D3receptors with preferential binding to the D3receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A. Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
